Key Takeaways:
- Stanford researchers found an existing FDA-approved drug could prevent muscle loss during GLP-1 treatment while maintaining weight loss benefits
- Young adult mice receiving the companion drug alongside a GLP-1 exhibited improved muscle regeneration and recovery of strength after muscle damage without undermining fat loss
- The compound has been deemed safe by the Food and Drug Administration and is already in clinical trials for age-related muscle loss
- This discovery could eliminate the need to choose between rapid weight loss and muscle preservation
Major Discovery Addresses GLP-1 Side Effect
Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss. But while these drugs deliver remarkable weight loss results, many are quietly losing something else along with the fat: muscle.
Now, Stanford Medicine researchers have published findings that could solve this problem. In a study published on June 2 in Proceedings of the National Academy of Sciences, the team discovered that an existing FDA-approved drug could serve as a companion treatment to prevent muscle loss during GLP-1 therapy.
"There is a major unmet need for a drug that can help GLP-1 users preserve their muscle health and strength," said Helen Blau, PhD, professor of microbiology and immunology at Stanford and the study's senior author.
How the Companion Drug Works
The Stanford team tested their approach in obese mice treated with semaglutide (the active ingredient in Wegovy and Ozempic). Obese mice that were treated with semaglutide lost about 25% of their body weight and substantially reduced their fat levels. Semaglutide also reduced skeletal muscle mass.
When the researchers added their experimental compound—a drug called a PGDHi (15-hydroxyprostaglandin dehydrogenase inhibitor)—the results were remarkable. Young adult mice receiving the drug alongside a GLP-1 exhibited improved muscle regeneration and recovery of strength after muscle damage without undermining fat loss.
The drug works by enhancing the muscle's natural repair mechanisms. "PGDHi enhanced that regenerative response even in the setting of semaglutide-induced weight loss," according to Stanford's research findings.
Why Muscle Loss Matters for GLP-1 Users
The muscle loss associated with rapid weight loss medications isn't a cosmetic concern—it has serious health implications. Unlike fat, muscle doesn't return quickly, and muscle loss can have deleterious effects on strength, mobility and overall health.
While muscle loss didn't translate to a loss of strength under normal conditions in the Stanford study, the real test came when muscles were damaged. That's where the companion drug showed its value, helping muscles regenerate more effectively during the healing process.
This finding is particularly relevant as more people turn to semaglutide injection and other GLP-1 medications for weight management. The research suggests that preserving muscle during weight loss could help people maintain their strength and mobility long-term.
Muscle mass affects your metabolism, bone density, and ability to perform daily activities. When you lose muscle during weight loss, your body burns fewer calories at rest, which can make it harder to maintain your new weight over time.
Timeline for Human Applications
The most encouraging aspect of this discovery is how quickly it could reach people taking GLP-1 medications. The compound has been deemed safe by the Food and Drug Administration and is already in clinical trials for age-related muscle loss.
The experimental compound could become a standard companion to GLP-1 drugs, potentially transforming how healthcare providers approach weight loss treatment. Instead of choosing between rapid weight loss and muscle preservation, people might soon have both.
However, the drugs have yet to be tested in older obese individuals, who have different risk factors for muscle loss. This means additional studies will likely be needed before the companion therapy becomes widely available.
The research team expects human trials specifically for GLP-1 muscle preservation to begin within the next 18-24 months, given the drug's existing safety profile and current clinical testing for other conditions.
Current Solutions for Muscle Preservation
While waiting for this companion drug to become available, healthcare providers are developing comprehensive strategies to help GLP-1 users maintain muscle mass. These approaches include structured resistance training programs, targeted protein supplementation, and careful monitoring of body composition throughout treatment.
Many providers now recommend consuming 1.2-1.6 grams of protein per kilogram of body weight daily and engaging in strength training exercises at least twice weekly while taking GLP-1 medications. Some are also exploring timing strategies for meals and exercise to optimize muscle protein synthesis during weight loss.
The cost of comprehensive GLP-1 programs that include muscle preservation support varies, but many providers are recognizing that addressing muscle loss upfront prevents more expensive health complications down the road.
What This Means for You
If you're currently taking or considering GLP-1 medications like Wegovy, Ozempic, or Zepbound, this research offers hope that muscle loss doesn't have to be an inevitable trade-off for weight loss. While the companion drug isn't yet available for this specific use, the findings suggest that effective solutions are on the horizon.
Work with your healthcare provider to develop a comprehensive approach that includes resistance training and adequate protein intake to help preserve muscle during your weight loss process. If you're exploring GLP-1 options, you can compare telehealth providers to find services that offer comprehensive support for muscle preservation alongside medication management.
Consider tracking your body composition, not weight alone, throughout your treatment. Many people find that focusing on muscle preservation while losing fat leads to better long-term outcomes and improved quality of life.
"We're on the way to tackling a major and unwanted side effect of GLP-1 drugs: losing muscle strength along with fat," Blau noted, highlighting the potential for this research to transform weight loss treatment in the near future.
Sources
- Stanford Medicine News - Drug enhances muscle repair during GLP-1 weight-loss treatment in mice
- Medical Xpress - Existing drug enhances muscle repair during GLP-1 weight-loss treatment in mice
- Stanford Report - Research offers hope for muscle recovery in GLP-1 patients